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Abstract: The magnetization of mesenchymal stem cells (MSC) has the potential to aid tissue
engineering approaches by allowing tracking, targeting, and local retention of cells at the site of
tissue damage. Commonly used methods for magnetizing cells include optimizing uptake and
retention of superparamagnetic iron oxide nanoparticles (SPIONs). These appear to have minimal
detrimental effects on the use of MSC function as assessed by in vitro assays. The cellular content of
magnetic nanoparticles (MNPs) will, however, decrease with cell proliferation and the longer-term
effects on MSC function are not entirely clear. An alternative approach to magnetizing MSCs
involves genetic modification by transfection with one or more genes derived from Magnetospirillum
magneticum AMB-1, a magnetotactic bacterium that synthesizes single-magnetic domain crystals
which are incorporated into magnetosomes. MSCs with either or mms6 and mmsF genes are
followed by bio-assimilated synthesis of intracytoplasmic magnetic nanoparticles which can be
imaged by magnetic resonance (MR) and which have no deleterious effects on MSC proliferation,
migration, or differentiation. The stable transfection of magnetosome-associated genes in MSCs
promotes assimilation of magnetic nanoparticle synthesis into mammalian cells with the potential
to allow MR-based cell tracking and, through external or internal magnetic targeting approaches,
enhanced site-specific retention of cells for tissue engineering.
Keywords: mesenchymal stem cells; magnetic nanoparticles; magnetotactic bacteria; magnetosomes;
tissue engineering
1. Introduction
Due to their unique physical properties, magnetic nanoparticles (MNPs) are being increasingly
recognized as having potential in a range of biomedical applications either alone or through cell-based
therapies [1]. They are typically composed of a magnetite (Fe3O4) or maghemite (γ-Fe2O3) core.
Both are naturally ferromagnetic in bulk, being permanently attracted to magnets or are permanently
magnetic, but at diameters smaller than their intrinsic superparamagnetic radius and greater than
their single domain radius, they become superparamagnets. In general, iron oxide MNPs smaller
than 30 nm are superparamagnetic, i.e., their magnetization only occurs in the presence of an external
magnetic field and are termed superparamagnetic iron oxide nanoparticles (SPIONs). The magnetic
responsiveness of MNPs allows them to be identified by magnetic resonance (MR) imaging and as
such they are useful for tracking the destination and fate of loaded cells such as stem cells used in
tissue engineering applications [2]. The use of internal or external magnetic forces following in vivo
administration of magnetic stem cells may also allow targeting to specific sites of interest such as areas
of tissue damage improving efficacy of treatments [3]. In this review, we look at the potential for the
use of genetically modified magnetic mesenchymal stem cells for tissue engineering.
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2. Extrinsic Magnetization
Finding the optimal method to magnetize human mesenchymal stem cells (MSCs) for tissue
engineering or other cell-based therapies has proved challenging. Unmodified SPIONs are readily
taken up by phagocytic cells such as macrophages but this contrasts to the relatively poorer ability
of non-phagocytic cells such as MSCs to ingest extrinsically applied MNPs and the possibility of
adverse effects on MSC proliferation and migration [1]. A number of strategies have been developed
to increase uptake of MNPs by non-phagocytic cells such as MSCs. These include coating of the MNPs
with a range of substances including surfactant, precious metals, silica, carbon coatings, cellulose,
and chitosan. Currently, three prominent SPION coating types—polyethylene glycol (PEG), starch,
and dextran—appear to be most beneficial and generally used [2,3] with ferumoxide, ferucarbotran,
and Feridex SPIONs coated with being approved for human use. Cellular uptake of MNPs is by
endocytosis but may be enhanced by the use of agents traditionally used for gene transfection such
as Fugene, Superfec and Lipofectamine [4]. Furthermore, cell labelling with transfection agents has
saturation effects, requiring a high concentration of transfection agents and a long incubation period,
which may have a negative effect on cell function after transplantation [5]. However, uptake of MNPs
by MSCs is variable over a population and cell content is likely to decrease following proliferation
of administered MSCs in vivo. Nanoparticles may also be released from cells and thereafter drain to
lymphatics or be taken up by neighboring tissue cells. Potential detrimental effects on cell proliferation
and migration [1] are continually debated with more recent reports indicating less adverse effects on
cell behavior [6–9], although their long-term in vivo effects need to be fully evaluated. Nevertheless,
there is a significant body of literature indicating that metallic nanoparticles have cytotoxic potential
with SPION accumulation affecting cell differentiation and inducing oxidative stress to cells [10].
The impact of SPIONs on MSC function, such as proliferation, immunomodulation, and differentiation,
are being explored. Ferucarbotran, a SPION with a crystalline nonstoichiometric Fe2+ and Fe3+ iron
oxide core, stimulates in vitro MSC proliferation [11–13], whereas other iron oxide nanoparticles have
been shown to enhance osteogenic differentiation in human bone-derived mesenchymal stem cells
(hBMSCs) in vitro [14]. More work is clearly required in this area to establish the effects of different
MNPs over a range of concentrations on specific MSC function and differentiation.
3. Intrinsic Magnetization
3.1. Magnetotactic Bacteria and Magnetosomes
To overcome at least some of the above problems, there has been recent interest in the generation
of human MSCs capable of synthesizing de novo magnetic nanoparticles based upon processes used
by magnetotactic bacteria (MTB). MTB are Gram-negative organisms, initially identified by Salvatore
Bellini, which are able to align with external magnetic fields. This ability is given by chains of linearly
arranged subcellular magnetic organelles, called magnetosomes [15–18]. Magnetosomes are lipidic
membranes, originating from MTB cytoplasmic membrane [19,20] containing crystals of either magnetite
(Fe3O4), greigite (Fe3S4), or maghemite (γ-Fe2O3). The length of the magnetosome crystal iron oxide
core, determined by Transmission Electron Microscopy (TEM) investigation, measures between 5 and
120 nm. Magnetospirillum magneticum AMB-1 and Magnetospirillum gryphiswaldense MSR-1 strains are
characterized by magnetosomes of cubo-octahedral geometry, sized between 30 and 50 nm [21]. This size
makes magnetosomes single-domain crystals with the maximum possible magnetic moment per unit
volume. In Magnetospirillum AMB-1 and Magnetospirillum MSR-1, there is only one magnetosome chain
composed by 15–30 magnetosomes, while the Magnetobacterium bavaricum strain shows more chains,
each of them consisting of more strands of magnetosomes [22].
Magnetosome formation is a multi-step process involving invagination of vesicles from the inner
membrane; sorting and targeting of magnetosome membrane proteins to the forming structure;
iron transport; crystallization of magnetite crystals; assembly, as well as positioning of formed
invaginations into a chain-like structure (Figure 1).
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Figure 1. Sequential steps in the formation of agnetosomes in magnetotactic bacteria.
Essential genes for the biosynthesis of magnetosomes in MTB are clustered predominantly in
large genomic units called the magnetosome gene island (MAI) [15]. This conserved region contains
a number of operons including agnetosome embrane (mam) AB (17 genes), mamGFDC (4 genes),
and mamXY (4 genes), the agn tic particle membrane-specific (mms) operon mms6 (5 genes) and
the monocistronic mamW operon [23]. Without MAI or the operon mamAB, there is no magnetic
phenotype [24,25]. Studies have shown that the large mamAB operon is predominantly involved in iron
transport, magnetosome membrane biogenesis, and crystallization of magnetite particles, as well as
their chain-like rganization and intracellular positioning, whereas the smaller mamGFDC, mms6 and
mamXY operons are mainly associated with the formation prop rly sized and crystals morphology [19].
Magnetosome membrane formation from the inner cell membrane is important magnetosome
biomineralization acting as a “nano-reactor” for crystal formation [26] by facilitating the creation
of the chemical conditions required for the biomineralization and protection against cytotoxicity.
Magnetos me vesicles remai as invaginations al ng the entire mineralization process, being initially
empty or, in latter stages, containing iron. The formation f vesicles app ars to b a necessary
condition for the biomineralization process although vesicles may be seen as MTB in iron-deprived
conditions [24,27]. Magnetosome proteins are usually targeted to the magnetosome membrane or to
the cytosolic side. MamA, a highly conserved magnetosome-associated protein, acts as a multiprotein
interacti n site, forming homo-oligomers with central pore cavity [28]. MamE, p edicted to be an
integral membrane protein containi g a tr nsme brane region, has a role in protein sorting and
initiation of biomineralization [29], a stepwise process involving nucleation, growth, and regulation
of crystal morphology [30]. Iron accumulation in magnetosome membrane vesicles appears to occur
subsequently to iron uptake [26] and formation of agnetite is favored within a narrow redox range
with a 2/1 ratio of Fe3+/Fe2+. M gA is a putative iron transporter [31] but recent gen t c experiments
have shown that magnetosomes in magA-deletion mutants resemble those of wild-type cells [32].
Complete understanding of crystal growth and regulation within magnetosomes is ongoing but
it is clear that the process is tightly controlled. Some proteins, even if not directly involved in the
magnetosomes biomineralization process, play a role in the determination of magnetoso e size and
morphology [33]. Genetic studies have shown that smaller magnetite crystals are formed in mutants
that lack MamS, MamR, MamN, MamF, Mms-F, Mms5, Mms6, or Mms7. Mms5, Mms6, Mms7,
and Mms13 have been identified as being in the magnetite biomineralization process. Mms proteins
localize to the magnetosome membrane and are located on the surface of synthesized cubo-octahedral
crystals synthesized in Magnetospirillum magneticum strain AMB-1 [30,34,35]. Mms7 plays key
roles in the control of magnetite crystal growth and morphology of magnetite crystals in MTB [36].
Both mms6 and mmsF are contained within the mms6 operon and their contribution to magnetosome
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biogenesis is beginning to be understood [37]. Mms6 differs from other Mms proteins as it presents
a negative charge at neutral pH, the others being positively charged [34]. The sequence of the
mms6 gene shows a high consensus among different MTB species [38], especially in the C-terminal
region. The mass of the protein coded by mms6 is 12–15 kDa, somewhat larger than the 6 kDa
Mms6 protein identified by SDS/PAGE, suggesting that Mms6 undergoes post-transcriptional
protease cleavage [34,39]. The predicted secondary structure of Mms6 is that of an unstructured
N-terminal domain, a transmembrane helix and a C-terminal which may form an α-helix structure [15].
The presence of the helix is supported by protein model structure and sequence analysis, while 3D
models show a negative patch on its carboxy-terminal domain (CTD) that is believed to be an iron
binding site [15]. The Mms6 protein is embedded on the interior of the magnetosome membrane
and is tightly associated with the formed mineral. Mms6 promotes the formation of uniform
isomorphic superparamagnetic magnetite nano-crystals and helps regulate the crystal morphology of
magnetite [25]. Possible roles for Mms6 in recruitment of other Mms proteins to the magnetosome and
in magnetite crystal nucleation have also been proposed [35,40,41].
Significantly, recombinant Mms6 binds iron and, using either room temperature co-precipitation
or partial oxidation of ferrous hydroxide, aids formation of magnetite particles in vitro that are
similar to those of magnetosomes [34,37]. Analysis of gene deletion mutants and transformants of
Magnetospirillum magneticum AMB-1 expressing partially truncated Mms6 protein reveals that deletions
in the N-terminal or C-terminal regions disrupt proper protein localization to the magnetite surface,
resulting in a change in the crystal morphology [42]. Staniland and Rawlings have recently proposed a
mechanism for the function of Mms6 as a specific magnetite nucleation protein and have highlighted
key features for this action including self-assembly to display a charged surface for specific iron
binding, with the curvature of the surfaces determining the particle size [38].
Less is known regarding the function of MmsF. In M. Magneticum AMB-1, mmsF is located directly
downstream to mms6, separated from it by only 17 nucleotides. No promoter is identified upstream of
mmsF, so mms6 and mmsF are possibly co-transcribed [43]. MmsF is an α-helical membrane spanning
protein. It self-assembles in vitro into 36 nm diameter spherical aggregates that control nanoparticle
size and magnetite homogeneity in chemical precipitation reactions, supporting its indicated in vivo
role as a master regulator of magnetite biomineralization and nanoparticle morphology [44].
3.2. Formation of Magnetosome-Like Nanoparticles in Mammalian Cells
As yet, relatively few magnetosome-associated genes have been tested in mammalian cell systems,
with the limited number of published studies having focused on magA or mms6. magA from two
different MTB has been studied as a potential reporter gene for Magnetic Resonance Imaging (MRI),
whereas mms6, and to a lesser extent mmsF, have been assessed for nanoparticle production in human
mesenchymal stem cells.
Transgenic studies using the magA gene isolated from AMB-1 MTB demonstrated that stable
transfection of the human embryonal kidney cell line and a mouse neuroblastoma N2A cell line led
to deposition of intracellular iron that could function as a MRI reporter [45,46]. Accumulation of
intracellular iron was dependent on iron supplementation and gene expression. Produced nanoparticles
of around 250–450 nm were found throughout the cytoplasm of cells but were most easily identified
within membrane-enclosed structures [45]. Magnetic separation and X-ray powder diffraction indicated
that the particles were magnetic and consisted primarily of magnetite. mms6 has also been shown to act
as a MR reporter when transfected into a cancer cell line, with mms6-expressing cells forming clusters of
nanoparticles within and outside membrane-enclosed structures [47].
Unfortunately, in these studies, cancer cell lines or embryonal kidney cells, rather than stem
cells, were studied and magnetic behavior of the particles produced by the transfected cells was not
demonstrated by superconducting quantum interference device (SQUID) magnetometry. Nevertheless,
these studies have been important in demonstrating the potential of a transgenic approach to
magnetizing MSCs for clinical purposes.
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3.3. Biosynthesis of Magnetic Nanoparticles by Human Mesenchymal Stem Cells
Recent studies by our group have shown the potential of using a transgenic approach to magnetize
MSCs by transfection with either or both the mms6 and mmsF genes [48] derived from Magnetospirillum
magneticum AMB-1, a magnetotactic bacterium that synthesizes single-magnetic domain crystals which
are incorporated into magnetosomes. These studies involved transfecting human MSCs with modified
mms6 or mmsF genes, after which gene expression studies, assessment of nanoparticle production and
effects on MSC function were established (Figure 2).
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Figure 2. Workflow for induction and asses ment of magneti ticle roduction in human
mesenchymal stem cells (MSCs) following m s6 gene transfectio .
The Magnetospir llum AMB-1 ms6 and mmsF DNA bacterial sequ nces were
cod n-optimized for mammalian expression and a Kozak s quence add d, then syn hesized.
The optimized sequence was synthesized and cloned in their proprietary vector with Sa I a d KpnI
restriction sites. The synthetic genes were then cloned into a pcDNA3.1 expression vector at BamH1
and EcoRI restriction sites. The pcDNA3.1 expression vectors were transfected either alone or together
as separate plasmids into human adipocyte-derived MSCs with either X-tremeGENE HP or FugeneHD.
The transfected MSCs were cultured with the addition of 3.4 µL/mL of ferric quinate solution to a final
concentration of 34 µM, ferric quinate being used as standard as a source of iron for magnetobacterial
culture and magnetosome formation [49].
RT-PCR confirmed expression of both genes from day 7 to day 21 in culture which was associated
with accumulation of membrane-bound, intracytoplasmic electron-dense nanoparticles identified by
transmission electron microscopy (TEM) (Figure 3). MSCs expressing mms6 and mmsF genes contain
vesicles filled with both dispersed and larger electron-dense material with vesicles measuring up to
1 µm in diameter. Image analysis studies showed an increase in the amount of electron-dense material
within cytoplasmic vesicles of mms6 transfected cells from day 10 to day 15 in culture without an
increase in material deposition thereafter (Figure 4). In vitro phantom studies on mms6-transfected
cells following 21 days in culture in the presence of ferric quinate indicated that cells were identifiable
by MRI, confirming previous studies that mms6 could act as a MR reporter gene. Atomic force
microscopy/mag etic force microscopy (AFM/MFM) indicated that the synthesized n noparticles
within mms6-transfected cells were magnetic (Figure 5) in c ntrast to MSCs incubated with F Cl3 and
untransfect d MSCs in which no magnetic structures were identified [48]. To further characterize the
magnetic nature of the intracytoplasmic particles, we have used SQUID magnetometry which easures
the total magnetic moment of a sample, including all atomic and molecular magnetic contributions.
Results of these measurements for MSCs 21 days after transfection confirmed the magnetic nature
of the cellular nanoparticles of the nanoparticles synthesized by the mms6- and mmsF-transfected
cells [48]. The mms6-transfected MSCs appear to show greater magnetism than mmsF-transfected
MSCs with mms6/mmsF co-transfected MSCs showing least magnetism (unpublished results).
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To assess whether mms6 transfection and induction of magnetic nanoparticle production
might have ff cts on MSC function that would have adversely influe c d their ability to
aid specialized tissue repair, studies on cell proliferation, migration, and differentiation have
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been undertaken. No adverse effects on MSC proliferation or migration have been identified.
FACS analysis showed no change in phenotype with respect to expression of the cell surface
markers ecto-5-prime-nucleotidase/CD73, Thy1-antigen/CD90 or endoglin/CD105 up to 21 days
post transfection. (Table 1). When mms6-transfected MSCs are cultured for 3 weeks in osteogenic
media expressed alpha-1 type I collagen (COL1A1) and bone gamma-carboxyglutamic acid-containing
protein (BGLAP) and stained positively with von Kossa stain, it indicates maintenance of osteogenic
differentiation potential. Chondrogenic differentiation of transfected MSCs was established by
culturing transfected MSCs in chondrogenic media where expression of COL2A1 and ACAN was
evident and proteoglycan synthesis was demonstrated, whilst culture in adipogenic media resulted
in expression of Peroxisome proliferator-activated receptor gamma (PPARG) and oil-red O staining,
indicating that the transfected MSCs maintained the capacity for specific lineage differentiation [48].
Table 1. Expression of MSC differentiation antigens following 21 days in culture. Wild-type or
transfected MSCs were cultured in the absence or presence of ferric quinate.
Differentiation Antigen Non-Transfected MSCs Non-TransfectedMSCs with FeQ
mms6-Transfected
MSCs with FeQ
CD34 3.1 ± 0.1 2.9 ± 0.3 3.2 ± 0.2
CD73 99.9 ± 0.1 99.8 ± 0.1 99.8 ± 0.1
CD90 99.9 ± 0.1 99.6 ± 0.1 98.1 ± 0.1
CD105 98.8 ± 0.1 98.7 ± 0.1 98.3 ± 0.1
These studies have demonstrated proof of concept that MTB magnetosome-associated genes can
be expressed in human MSCs but studies with His and Green Fluorescence Protein (GFP)-tagged
mms6 genes show decreased protein production with time in culture, most likely as a consequence
of transient gene expression (Figure 6). As such, for longer, in vivo-related studies it is important to
develop stable expression cells as has been done for magA. This should allow increased gene expression,
elevation in protein production, and enhanced formation of magnetic nanoparticles. Continued gene
expression in MSC progeny would also maintain cell magnetism and potentially aid the tracking,
localization, and retention of magnetic MSCs over a prolonged period. To this end, we have created a
lentiviral construct which has allowed stable expression of Mms6 in MSCs. These transduced cells
contain intracytoplasmic nanoparticles and can be imaged by MR (Figure 7).
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4. Tracking, Localization, and Retention of Magnetic MSCs
The self-renewal capabilities and multidirectional differentiation potential of MSCs make them
ideal for cell-based therapy in regenerative medicine as they may be induced under different conditions
to differentiate into a range of tissues such as bone, cartilage, adipose, muscle, endothelial, and nerve
tissue. However, optimal effectiveness of cell-based therapy depends upon MSCs being delivered
to and retained at the site of interest where they need to be appropriately induced to differentiate.
Although MSCs selectively migrate towards damaged tissue, long-term retention at sites of injury
following systemic or local administration of MSCs can be poor [50]. There is therefore an increasing
requirement to identify both the fate of the therapeutic cells following delivery and, where possible,
retain these cells optimally at the site of tissue damage/repair [51–55]. In vitro labelling of stem cells
with magnetic iron oxide particles or by transgenic approaches [55,56] allows in vivo imaging by MR,
whereas magnetic targeting (MT) may enhance attraction and retention of labelled cells by application
of a magnetic field over the area of interest following either local or systemic injection.
4.1. MR Imaging
Magnetic resonance imaging allows high-resolution visualization of appropriately labelled MSCs
when delivered in vivo [57]. Several types of contrast agents added to MSCs have been used for MRI
in vivo imaging. These include SPIONs but the potential of a transgenic approach to magnetizing
MSCs for MR imaging is also under active consideration [56]. Cells transfected with magA, cloned from
both MS-1 and AMB-1 species of MTB, show increased MR contrast in stably transfected mammalian
cells, in response iron supplementation [45,46]. Mms6 has also been studied as a potential reporter
gene. Expression in a mammalian cell line allowed differentiation, in vivo, of tumors that stably
expressed mms6 from those that did not, even in the absence of exogenous iron supplementation [47].
Our in vitro results with transgenic MSCs confirm that mms6 can function as a MR reporter gene with
the potential to allow MR tracking in vivo [48].
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4.2. Magnetic Targeting
The type of magnetic device used to target MSCs will change depending on the body location
to which the cells are to be targeted. Magnetic targeting relies on magnetization of MSCs followed
by in vivo targeting with the aid of magnetic fields with the aim to allow and retain the maximum
number of cells administered to reach the site of required repair, allowing limitation of the cell
number and volume injected [58]. Typically, this may be with an external magnet [59,60] but
increasingly magnetic implants are being developed, as in the orthopedic field where insertion of
magnetic scaffolds with or without permanent magnets can be used to aid healing of massive bone
defects and chondro-osseous defects [61]. In vivo guidance of the magnetized MSCs by external static
magnetic fields for magnetic targeting can be through the use of permanent magnets or electromagnets,
although permanent magnets are likely to be preferred since they are portable, reach higher field
strengths compared to electromagnets of similar size, and do not require a power supply or cooling
system. Permanent magnets are normally placed externally, with multiple magnets sited in different
positions in relation to the area of interest, allowing a static magnetic field to be extended to deeper parts
of the body. The use of external magnets for MT is now reaching the clinic [62,63]. Kamei et al. [63] used
autologous bone marrow MSCs magnetized with Ferucarbotran with an external 1.0 Tesla compact
magnet for treatment of knee joint cartilage defects in 5 patients. 1× 107 MSCs were injected into the
knee joint and the magnet was maintained in the same position for 10 min after the MSC injection.
There were no significant initial adverse effects and outcomes, with respect to cartilage repair and
clinical outcome, after 48 weeks were good. While external magnets avoid the risk of an inflammatory
response to the inserted materials, proof-of-principle studies have indicated that implanted permanent
magnets and scaffolds have potential in a range of settings including bone repair [61,64–66]. In addition
to enhancing targeting and retention of magnetic MSCs, magnetic fields may directly enhance MSC
functionality. In vitro studies have demonstrated enhanced cell adhesion, viability, proliferation,
secretory activity, as well as differentiation potential [67–69] when MSCs are exposed to an external
magnetic field, effects which appear in part to be mediated through a phosphoinositide 3-kinase/Akt
signaling pathway [70].
5. Magnetic MSCs and Hyperthermia
Hyperthermia is a therapy in which heat is increased within a tumor to an extent that elevation of
the local temperature into a range of 41–56 ◦C induces a range of cellular changes including protein
denaturation, damage to the cytoskeleton, disruption of DNA repair which lead to cell death via
apoptosis or necrosis [71–73]. Other beneficial effects include stimulation of the immune system [74].
The use of hyperthermia for cancer treatment has benefits in that the toxic side effects are less than
that of chemotherapy and radiotherapy. Furthermore, cancer cells are more sensitive to increases in
temperature than the surrounding healthy cells, a characteristic which may relate to altered vasculature
within tumors [75,76].
A number of different techniques have been used to induce hyperthermia, including application
of microwaves, radio waves, or ultrasound [77], but there is an increasing interest in the development
and use of magnetic hyperthermia (MH) therapy for a number of difficult-to-treat cancer types such
as glioblastoma and in the management of a diverse range of primary, recurrent, and metastatic
tumors that are not amenable to standard surgical, radio- or chemotherapy treatment [78,79]. MH is
based on the concept that MNPs generate heat when exposed to an external alternating magnetic
field (AMF). There are two mechanisms recognized as being responsible for heat production by MNPs
in an external magnetic field. These are the magnetic hysteresis loss, occurring in particles with
multimagnetic domains, and Néel and Brownian relaxation that are present in superparamagnetic
or single-domain particles [80]. Local hyperthermia is thereby produced due to the rotation of
the nanoparticles (Brownian relaxation) and flipping of the magnetic dipoles due to rotation of
the magnetic moments in the magnetic field (Néel relaxation) [81]. Intratumoural-injected MNPs
generate heating effect after application of an external magnetic field and induce cell death [82,83].
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MNPs used for MH are typically metals such as iron, cobalt, and nickel and metal oxides including
Fe3O4, γ-Fe2O3, MnFe2O4, and CoFe2O4. However, as degradation of MNPs within the body results
in the production of reactive oxygen species (ROS) and free radicals which trigger lipid peroxidation,
DNA damages, protein alteration, and cell apoptosis, MNPs are usually subjected to a range of surface
modifications that increase stability and safety. These include coating with dimercaptosuccinic acid
(DMSA), polyethylene glycol (PEG), dextran, chitosan, liposomes, gold, or silica, which function to
decrease agglomeration, increase biocompatibility and pharmacokinetics [84].
Magnetosomes have also been studied for MH treatment of tumors [2]. Application of an AMF of
frequency 183 kHz and field strengths of 20, 40, or 60 mT to the MDA MB 231 breast cancer cell line
to which extracted chains of magnetosomes had been added induced up to 100% cell death of these
cells in vitro. Importantly, similar efficacy was seen in vivo when three 20 min cycles of MH were
applied following injection of a suspension containing ∼1 mg of extracted chains of magnetosomes
into a tumor arising following subcutaneous inoculation of the breast cancer cell line [85]. In this
study, tumor regression was seen with elevation of local temperature to 43 ◦C. Recently, magnetosomes
which have been made biocompatible by removing potentially toxic organic bacterial residues and by
coating with poly-L-lysine, leading to magnetosomes-poly-L-lysine have been used in MH preclinical
studies [86]. Injection of 25 µg iron of nanoparticles per mm3 of tumor and application of 11 to 15
30 min sessions of 198 kHz, 11 to 31 mT, AMF resulted in significant longer-term survival in around
50% of mice.
Challenges limiting the clinical use of MH, however, include obtaining adequate and reproducible
localization of MNPs to the tumor site and improving the specific heating power of MNPs in
order to use the minimum required amount of MNPs [87]. MNP administration has traditionally
been by direct intratumoural injection or through an intravenous route. Direct intratumoural
injections have the advantage of achieving high local concentrations of MNPs and limiting systemic
toxicity. Disadvantages of this approach include inhomogeneous intratumour distribution potentially
preventing complete eradication of tumors following induction hyperthermia and its non-applicability
to treatment of multifocal metastatic disease. Although intravenous administration has the potential
to cover irregular tumor shapes more precisely, MNPs are rapidly removed from the blood stream
by the reticuloendothelial system and doses required to lead to significant loading of tumor tissue
for induction hyperthermia tend to be systemically toxic. Locally injected MNPs also redistribute
following administration. To overcome at least some of these problems, the idea of using cells as
carriers of MNPs is gaining acceptance. When RAW264.7 mouse monocyte/macrophage-like cells
were loaded with iron oxide nanoparticles and injected into the peritoneum of mice bearing pancreatic
tumors, there was preferential homing of the MNP-bearing cells to the tumors with limited spread
to normal organs [88]. There is now compelling evidence that MSCs can be utilized as delivery
vehicles for cancer therapeutics taking advantage of their innate tropism to the tumor site and their low
immunogenicity. Human MSCs administered through a tail vein have been shown to preferentially
engraft at tumor sites [89]. Observations that some studies have failed to detect MSC tumor-homing
from intravenous injection whereas extensive MSC migration within gliomas following intratumoural
injection indicates that direct in situ administration of MNP-bearing MSCs may have potential in the
clinical setting for MH [90]. It remains unclear whether MSCs can be used as a delivery system for
MNPs in cancer treatment. A recent study failed to show a significant differences in overall tumor
size or growth characteristics in a mouse model using Ferucarbotran-loaded human MSCs despite
labeled MSCs being incorporated into and retained within the tumors [91]. Although magnetosomes
have been shown to have a magnetic hyperthermia effect, the efficiency magnetosome chains appear
to be greater in the killing of tumor cells than individual, separated magnetosomes due to better
distribution within cells [90]. It remains to be seen whether genetically modified MSCs are able to
produce magnetic nanoparticles in sufficient amount and in an appropriate configuration to act as
suitable agents for MH.
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6. Conclusions
The use and potential of magnetic MSCs in tissue engineering is continually evolving with
necessary advances in cell magnetization technology. MSCs are able to be magnetized by the addition
of MNPs to cell cultures or through a transgenic approach using magnetosome-related genes from
magnetobacteria. A number of studies have now shown that magnetotactic bacterial genes are
expressed in mammalian systems and expression is associated with magnetic nanoparticle production
allowing MR imaging. Whether the transgenic expression of magnetic nanoparticles allows magnetic
targeting and what the long-term effects of these approaches on MSC function in vivo may be, however,
need to be understood. Certainly, improved methods of magnetic targeting of magnetized stem cells
through the use of external and internal magnets or magnetic scaffolds are likely to be essential for
optimal targeting and retention of magnetic MSCs for enhanced tissue repair.
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